Wedbush Initiates Coverage On Odyssey Therapeutics with Outperform Rating, Announces Price Target of $30
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.
Wedbush analyst David Nierengarten initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Outperform rating and announces Price Target of $30.